Physician profile
Katerina Bubnovsky
NPI 1144459165
$1,518.10
in general payments reported to CMS, 2019-2025
18 companies · $473 in 2025
The $473 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $31.90 · 2021: $157 · 2022: $13.53 · 2023: $159 · 2024: $446 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $567.52 | 2023-2025 | Infuse, Miebo, Xiidra |
| Dompe US, INC. | $336.98 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $129.80 | 2019-2025 | Precision7 |
| Coopervision INC. | $88.82 | 2019-2025 | Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $68.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $55.66 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $40.42 | 2019-2022 | |
| Maculogix, INC. | $33.22 | 2019-2021 | |
| Oyster Point Pharma, INC. | $32.34 | 2023-2024 | Tyrvaya |
| Alcon Research LLC | $31.07 | 2019 | |
| Sight Sciences, INC. | $29.56 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $18.29 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $14.69 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.51 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.90 | 2019 | |
| Shire North American Group INC | $12.69 | 2019 | |
| Integra Lifesciences Corporation | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katerina Bubnovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.